Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cerus Corp (CERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 499,219
  • Shares Outstanding, K 115,560
  • Annual Sales, $ 39,280 K
  • Annual Income, $ -62,910 K
  • 36-Month Beta 1.93
  • Price/Sales 10.20
  • Price/Cash Flow N/A
  • Price/Book 12.68

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.35 +20.00%
on 12/29/17
4.48 -10.27%
on 01/11/18
+0.33 (+8.94%)
since 12/15/17
3-Month
2.75 +46.18%
on 11/02/17
4.48 -10.27%
on 01/11/18
+0.92 (+29.68%)
since 10/16/17
52-Week
1.93 +108.29%
on 05/26/17
4.70 -14.47%
on 04/26/17
-0.27 (-6.29%)
since 01/13/17

Most Recent Stories

More News
Noteworthy Monday Option Activity: CERS, STMP, SIG

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cerus Corp. , where a total volume of 3,171 contracts has been traded thus far today,...

CERS : 4.01 (-7.18%)
Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017

Cerus Corporation (NASDAQ: CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2017 and provided 2018 product revenue guidance.

CERS : 4.01 (-7.18%)
Universal Health Grows Inorganically, Rising Costs a Drag

Universal Health's (UHS) top line grows on solid Acute Care and Behavioral Health platforms. Nevertheless, surging level of debt bothers.

UHS : 116.31 (-0.29%)
AMED : 56.71 (+3.56%)
CERS : 4.01 (-7.18%)
ALGN : 263.51 (+1.97%)
Zacks.com highlights: Drive Shack, Cerus, ReWalk Robotics, Aerohive Networks and Cloud Peak Energy

Zacks.com highlights: Drive Shack, Cerus, ReWalk Robotics, Aerohive Networks and Cloud Peak Energy

HIVE : 5.78 (-1.87%)
RWLK : 1.05 (-4.55%)
CLD : 5.30 (-4.50%)
CERS : 4.01 (-7.18%)
DS : 5.32 (-5.17%)
5 Breakout Stocks Offering Admirable Returns

Nearly as favored a strategy as it is divisive, picking breakout stocks is one of the most used techniques for active investors.

HIVE : 5.78 (-1.87%)
RWLK : 1.05 (-4.55%)
CLD : 5.30 (-4.50%)
CERS : 4.01 (-7.18%)
DS : 5.32 (-5.17%)
Cerus Corporation Receives IDE Approval to Initiate Phase III ReCePI Study

Cerus Corporation (NASDAQ: CERS) today announced it has received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate ReCePI (A...

CERS : 4.01 (-7.18%)
Technical Insights on Biotech Stocks -- Cara Therapeutics, Catabasis Pharma, Cerus, and Genocea Biosciences

If you want a Stock Review on CARA, CATB, CERS, or GNCA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Friday, benchmark US indices were in bullish...

CARA : 12.37 (-2.52%)
CATB : 1.50 (-2.60%)
GNCA : 1.08 (-4.42%)
CERS : 4.01 (-7.18%)
Cerus Corporation Reports Third Quarter 2017 Results

Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2017.

CERS : 4.01 (-7.18%)
Cerus to Present at Two Upcoming Conferences

Cerus Corporation (NASDAQ:CERS) announced today that management will present at two upcoming investor conferences:

CERS : 4.01 (-7.18%)
Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in Italy

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into an agreement with Kedrion Biopharma to distribute the full complement of INTERCEPT Blood System products in Italy....

CERS : 4.01 (-7.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company...

See More

Key Turning Points

2nd Resistance Point 4.48
1st Resistance Point 4.40
Last Price 4.01
1st Support Level 4.26
2nd Support Level 4.20

See More

52-Week High 4.70
Last Price 4.01
Fibonacci 61.8% 3.64
Fibonacci 50% 3.31
Fibonacci 38.2% 2.99
52-Week Low 1.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.